Cytosporone B is primarily studied for its potential anticancer properties. It acts as an activator of the nuclear receptor Nur77, a protein involved in regulating cell proliferation and apoptosis. By binding to Nur77, Cytosporone B can induce apoptosis in cancer cells, particularly in models of leukemia, breast cancer, and liver cancer. It has also shown promise in suppressing tumor growth in preclinical studies, making it a candidate for development as a chemotherapeutic agent. In addition to its anticancer effects, Cytosporone B exhibits anti-inflammatory and antidiabetic activities by modulating metabolic pathways and reducing inflammatory markers. Due to its ability to cross cell membranes easily and target specific nuclear receptors, it is considered a valuable scaffold for designing new bioactive molecules. Research is ongoing to improve its potency and selectivity for therapeutic use.